Optimizing Antiviral Therapy for COVID-19 with Learned Pathogenic Model

Overview

Journal Sci Rep

Specialty Science

Date 2022 Apr 28

PMID 35477965

Authors

Abhishek Dutta

Affiliations

Soon will be listed here.

Abstract

COVID-19 together with variants have caused an unprecedented amount of mental and economic turmoil with ever increasing fatality and no proven therapies in sight. The healthcare industry is racing to find a cure with multitude of clinical trials underway to access the efficacy of repurposed antivirals, however the much needed insights into the dynamics of pathogenesis of SARS-CoV-2 and corresponding pharmacology of antivirals are lacking. This paper introduces systematic pathological model learning of COVID-19 dynamics followed by derivative free optimization based multi objective drug rescheduling. The pathological model learnt from clinical data of severe COVID-19 patients treated with remdesivir could additionally predict immune T cells response and resulted in a dramatic reduction in remdesivir dose and schedule leading to lower toxicities, however maintaining a high virological efficacy.

Citing Articles

Reparameterized multiobjective control of BCG immunotherapy.

Yue R, Dutta A Sci Rep. 2023; 13(1):20850.

PMID: 38012252 PMC: 10682440. DOI: 10.1038/s41598-023-47406-z.

Mechanisms of Potential Therapeutic Utilization of Mesenchymal Stem Cells in COVID-19 Treatment.

Fang Y, Lao P, Tang L, Chen J, Chen Y, Sun L Cell Transplant. 2023; 32:9636897231184611.

PMID: 37395459 PMC: 10328058. DOI: 10.1177/09636897231184611.

Computational systems biology in disease modeling and control, review and perspectives.

Yue R, Dutta A NPJ Syst Biol Appl. 2022; 8(1):37.

PMID: 36192551 PMC: 9528884. DOI: 10.1038/s41540-022-00247-4.

COVID-19 waves: variant dynamics and control.

Dutta A Sci Rep. 2022; 12(1):9332.

PMID: 35661125 PMC: 9166180. DOI: 10.1038/s41598-022-13371-2.

References

Szemiel A, Merits A, Orton R, MacLean O, Pinto R, Wickenhagen A . In vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2. PLoS Pathog. 2021; 17(9):e1009929. PMC: 8496873. DOI: 10.1371/journal.ppat.1009929. View

Perelson A, Ribeiro R . Modeling the within-host dynamics of HIV infection. BMC Biol. 2013; 11:96. PMC: 3765939. DOI: 10.1186/1741-7007-11-96. View

Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y . Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020; 395(10236):1569-1578. PMC: 7190303. DOI: 10.1016/S0140-6736(20)31022-9. View

Charan J, Kaur R, Bhardwaj P, Haque M, Sharma P, Misra S . Rapid review of suspected adverse drug events due to remdesivir in the WHO database; findings and implications. Expert Rev Clin Pharmacol. 2020; 14(1):95-103. PMC: 7784780. DOI: 10.1080/17512433.2021.1856655. View

Zeitlinger M, Koch B, Bruggemann R, De Cock P, Felton T, Hites M . Pharmacokinetics/Pharmacodynamics of Antiviral Agents Used to Treat SARS-CoV-2 and Their Potential Interaction with Drugs and Other Supportive Measures: A Comprehensive Review by the PK/PD of Anti-Infectives Study Group of the European Society of.... Clin Pharmacokinet. 2020; 59(10):1195-1216. PMC: 7385074. DOI: 10.1007/s40262-020-00924-9. View

Pawelek K, Dor Jr D, Salmeron C, Handel A . Within-Host Models of High and Low Pathogenic Influenza Virus Infections: The Role of Macrophages. PLoS One. 2016; 11(2):e0150568. PMC: 4769220. DOI: 10.1371/journal.pone.0150568. View

van der Graaf P, Benson N . Systems pharmacology: bridging systems biology and pharmacokinetics-pharmacodynamics (PKPD) in drug discovery and development. Pharm Res. 2011; 28(7):1460-4. DOI: 10.1007/s11095-011-0467-9. View

Canini L, Conway J, Perelson A, Carrat F . Impact of different oseltamivir regimens on treating influenza A virus infection and resistance emergence: insights from a modelling study. PLoS Comput Biol. 2014; 10(4):e1003568. PMC: 3990489. DOI: 10.1371/journal.pcbi.1003568. View

Ke R, Zitzmann C, Ho D, Ribeiro R, Perelson A . In vivo kinetics of SARS-CoV-2 infection and its relationship with a person's infectiousness. Proc Natl Acad Sci U S A. 2021; 118(49). PMC: 8670484. DOI: 10.1073/pnas.2111477118. View

10.

Jose R, Manuel A . COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med. 2020; 8(6):e46-e47. PMC: 7185942. DOI: 10.1016/S2213-2600(20)30216-2. View

11.

Sanders J, Monogue M, Jodlowski T, Cutrell J . Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020; 323(18):1824-1836. DOI: 10.1001/jama.2020.6019. View

12.

Wilt T, Kaka A, MacDonald R, Greer N, Obley A, Duan-Porter W . Remdesivir for Adults With COVID-19 : A Living Systematic Review for American College of Physicians Practice Points. Ann Intern Med. 2020; 174(2):209-220. PMC: 7564604. DOI: 10.7326/M20-5752. View

13.

Dolken L, Stich A, Spinner C . Remdesivir for Early COVID-19 Treatment of High-Risk Individuals Prior to or at Early Disease Onset-Lessons Learned. Viruses. 2021; 13(6). PMC: 8224666. DOI: 10.3390/v13060963. View

14.

Xu T, Chen C, Zhu Z, Cui M, Chen C, Dai H . Clinical features and dynamics of viral load in imported and non-imported patients with COVID-19. Int J Infect Dis. 2020; 94:68-71. PMC: 7270709. DOI: 10.1016/j.ijid.2020.03.022. View

15.

Guan W, Ni Z, Hu Y, Liang W, Ou C, He J . Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020; 382(18):1708-1720. PMC: 7092819. DOI: 10.1056/NEJMoa2002032. View

16.

Sheahan T, Sims A, Graham R, Menachery V, Gralinski L, Case J . Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017; 9(396). PMC: 5567817. DOI: 10.1126/scitranslmed.aal3653. View

17.

Hernandez-Vargas E, Velasco-Hernandez J . In-host Mathematical Modelling of COVID-19 in Humans. Annu Rev Control. 2020; 50:448-456. PMC: 7526677. DOI: 10.1016/j.arcontrol.2020.09.006. View

18.

McDonagh M, Bell E . The survival and turnover of mature and immature CD8 T cells. Immunology. 1995; 84(4):514-20. PMC: 1415168. View

19.

Risitano A, Mastellos D, Huber-Lang M, Yancopoulou D, Garlanda C, Ciceri F . Complement as a target in COVID-19?. Nat Rev Immunol. 2020; 20(6):343-344. PMC: 7187144. DOI: 10.1038/s41577-020-0320-7. View

20.

Chen Z, Wherry E . T cell responses in patients with COVID-19. Nat Rev Immunol. 2020; 20(9):529-536. PMC: 7389156. DOI: 10.1038/s41577-020-0402-6. View